Lv3
300 积分 2021-11-25 加入
ICOS and OX40 Signaling Optimization Improves CAR-T Cell Persistence in Preclinical Models
1年前
已完结
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia
1年前
已完结
Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells
1年前
已完结
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
1年前
已完结
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial
1年前
已完结
NK cells join the anti-cancer armory
1年前
已完结
G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma
1年前
已完结
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
1年前
已完结
Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells
1年前
已完结
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
1年前
已完结
皖公网安备34019202002308
